Polarean Imaging PLC - medical imaging technology developer - announces the successful expansion of a new imaging service model to enable the use of Xenon MRI in pharma-sponsored research, alongside its partner VIDA Diagnostics. This coincides with its selection by a leading global pharmaceutical partner to utilise the new Xenon MRI clinical trial support services platform as part of a sub-study within a worldwide multicentre study trial testing an investigational lung therapy.

Current stock price: 1.25 pence, up 2.0% in London on Monday

12-month change: down 70%

Copyright 2025 Alliance News Ltd. All Rights Reserved.